UTv Videos

“With this study, we gained a better understanding of the features of third line therapy for overactive bladder, that patients find favorable and unfavorable,” says Anjali Kapur, MD.

“The short-term goals are really community building [and] relationship building,” says Randy Vince Jr, MD.

“I think anecdotally speaking there have been a lot of practices and states corroborating our results,” says Rutul Patel, DO, MS.

Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.

Physician Coach Support is a free resource that provides confidential, one-on-one peer support for clinicians.

Study authors found a rise in public interest in vasectomies, “particularly in states where abortion is or is expected to be prohibited.”

“One of the first pieces of advice I would give is to make sure you have the OR space available for the equipment,” says Jennifer A. Linehan, MD.

“We did not happen to find that vitamin D compared to placebo lowered the odds of having incontinence at year 2 or year 5. Nor did it lower the odds of having overactive bladder symptoms at year 5,” says Alayne Markland, DO.

“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.

“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.

“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.

“I think what becomes important with this is how we need to do our part in terms of not only engaging our non-urology colleagues to help in educating them about these most common problems in urologic conditions, but also really become [advocates] at the medical school level,” says Jessica Kreshover, MD.

“The leadership has really driven this program to be one of the best in the country,” says Casey Kowalik, MD.

Micha Yin-Zheng Cheng, MD, MPH, MS, discusses the background of the UCSF UReTER (UnderRepresented Trainees Entering Residency) Mentorship Program.

Danica May, MD, discusses positive feedback she has received from participants in the KU Department of Urology rotation.

“It’s always fun getting to interact with people from different programs and different areas and we want to make them feel as welcome as possible,” says Danica May, MD.

Among the topics touched on in the discussion are lifestyle considerations, medical therapy, and surgical options.

“I think my goal in doing all this research is to draw awareness to these problems and the disparities,” says Elisabeth M. Sebesta, MD.

“Health care disparities are very complex issues; it’s not like a linear cause-and-effect relationship,” says Elisabeth M. Sebesta, MD.

“[We] found that women were spending on average, nearly $35 a week on incontinence products in the highest symptom severity, which is a huge financial burden,” says Elisabeth M. Sebesta, MD.

“With an increase in medical and surgical therapies in younger individuals, health care providers must discuss fertility preservation options prior to affirmation therapy,” says Niki Parikh, MD, MBA, MSBA.

“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.

“These are men who are suffering in silence. Many of them are too embarrassed to ever discuss their sexual health problems,” says Mohit Khera, MD, MBA, MPH.

“We were surprised that only 43% of individuals believed fertility preservation to be important, but this could be due to the relatively low age of our respondents, with the majority being between 18 and 39 years old,” says Niki Parikh, MD, MBA, MSBA.

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

“There will always be changes. I'm entering my fourth cycle of recertification, and I can tell you that none of the 3 prior cycles were similar,” says David Joseph, MD.

“Guidelines are not a rulebook; they're a framework for how to think about a particular disease,” says Edward M. Schaeffer, MD, PhD.

"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

“We…feel that this is going to be very helpful to the diplomate as far as improving their knowledge base,” says David Joseph, MD.

“What was published in May of 2022 was version 4 of the 2022 guidelines,” says Edward M. Schaeffer, MD, PhD.